Pharmacological Application of Brain-Computer Interface: The Future of Neurotherapeutics and Drug Delivery

Saloni Ghodeswar, Payal Sayare, Divya Kurvekar, Prachi Raut, Krutika Channe, Dr. Vinod Thakare.

Nagpur college of Pharmacy

Abstract

Brain-computer interfaces (BCIs) represent a transformative convergence of neuroscience, engineering, and pharmacology that promises to revolutionize neurotherapeutics and precision medicine. These sophisticated systems establish direct communication pathways between neural tissue and external devices, enabling real-time monitoring of brain activity and targeted therapeutic interventions. The integration of BCI technology with pharmacological applications has opened unprecedented avenues for personalized drug delivery, closed-loop therapeutic systems, and neuropharmacological research. This review examines the fundamental principles of BCI technology, tracing its evolution from basic non invasive systems to advanced implantable devices capable of simultaneous neural recording, stimulation, and localized drug administration. We explore the multifaceted relevance of BCIs in pharmacology, including their applications in monitoring drug effects, optimizing dosing regimens, enabling spatiotemporally precise drug delivery, and facilitating the development of adaptive therapeutic strategies for neurological and psychiatric disorders. Recent advances have demonstrated the feasibility of miniaturized, wireless BCI systems equipped with microfluidic channels and neurochemical biosensors that can deliver pharmacological agents directly to specific brain regions while continuously monitoring neural responses. These closed-loop platforms represent a paradigm shift from traditional systemic drug administration toward intelligent, feedback-controlled neurotherapeutics. However, significant challenges remain, including biocompatibility concerns, long-term device stability, regulatory considerations, and the need for robust control algorithms. This review provides a comprehensive overview of current BCI technologies, their pharmacological applications, and future directions in this rapidly evolving field, highlighting the potential of BCI-mediated drug delivery systems to transform the treatment of neurological disorders, psychiatric conditions, and neurodegenerative diseases.

Keywords: Brain-computer interface; Neurotherapeutics; Drug delivery systems; Closed-loop pharmacotherapy; Implantable devices; Microfluidics; Neurochemical sensing; Precision medicine; Neuromodulation; Neuropharmacology

1. Introduction

1.1 Overview of Brain-Computer Interfaces

Brain-computer interfaces represent one of the most remarkable achievements at the intersection of neuroscience, bioengineering, and computational science. At their core, BCIs are sophisticated systems that establish direct communication pathways between the brain and external devices, bypassing traditional neuromuscular pathways . This direct neural interface enables bidirectional information flow: extracting information from neural activity to control external devices or decode cognitive states, and delivering information back to the nervous system through stimulation or pharmacological modulation [1]. The fundamental promise of BCI technology lies in its ability to restore lost function in individuals with neurological impairments, enhance human cognitive and motor capabilities, and provide unprecedented access to the brain's complex dynamics for therapeutic and research purposes.

The conceptual foundation of BCIs rests on three core functional components that work in concert to achieve seamless brain-machine communication. First, the recording component captures neural signals through various sensing modalities, ranging from non invasive electroencephalography (EEG) to invasive intracortical microelectrodes that detect individual neuron action potentials [2]. These sensors transduce the electrochemical activity of neurons into electrical signals that can be digitized and processed. Second, the decoding component** employs sophisticated signal processing and machine learning algorithms to extract meaningful information from the complex, high-dimensional neural data [3]. This decoding process identifies patterns associated with specific intentions, cognitive states, or pathological signatures, transforming raw neural activity into actionable control signals or diagnostic biomarkers. Third, the encoding or actuation component translates decoded information into outputs, which may include controlling external devices, generating sensory feedback through electrical stimulation, or most relevant to this review triggering localized drug delivery to modulate neural circuits [4].

BCIs can be categorized along multiple dimensions, with the degree of invasiveness being the most fundamental classification. Non invasive BCIs utilize external sensors, most commonly EEG electrodes placed on the scalp, to record electrical potentials generated by synchronized cortical activity . While offering excellent safety profiles and ease of application, non invasive approaches suffer from limited spatial resolution (typically centimeter-scale), susceptibility to noise and artifacts, and inability to access deep brain structures. Despite these limitations, non invasive BCIs have demonstrated clinical utility in applications such as motor imagery-based communication systems for individuals with locked-in syndrome and neurofeedback training for attention and motor rehabilitation [5]. Semi-invasive BCIs, also termed partially invasive or minimally invasive systems, employ electrocorticography (ECoG) electrodes placed on the cortical surface beneath the skull but above the brain tissue. These subdural or epidural electrode arrays offer superior signal

quality and spatial resolution compared to scalp EEG while avoiding direct penetration of neural tissue, representing a promising middle ground for clinical applications. Invasive BCIs utilize intracortical microelectrodes or depth probes that penetrate brain tissue to record from individual neurons or small neural populations [6]. These systems provide the highest spatial and temporal resolution, enabling single-unit recordings and precise stimulation, but carry greater surgical risks and face challenges related to tissue damage, immune responses, and long-term biocompatibility.

Recent years have witnessed the emergence of multimodal and multifunctional BCI platforms that integrate recording with therapeutic modalities. These next-generation devices combine neural sensing with electrical stimulation capabilities, creating bidirectional interfaces that can both read and write neural information [7]. The addition of microfluidic channels and miniaturized pumps has enabled the integration of localized drug delivery directly into neural probes, creating a powerful platform for spatiotemporally precise pharmacological interventions. Neurochemical biosensors, including electrochemical detectors and optical probes, can monitor neurotransmitter concentrations in real-time, providing feedback signals for closed-loop drug delivery systems [8]. This convergence of sensing, stimulation, and pharmacological capabilities within a single implantable platform represents a fundamental shift in how we conceptualize and implement neurotherapeutic interventions.

1.3 Relevance of BCI in Pharmacology and Therapeutics

The integration of BCI technology with pharmacological sciences represents a paradigm shift with profound implications for drug development, therapeutic optimization, and our fundamental understanding of neuropharmacology. Traditional systemic drug administration faces inherent limitations when targeting the central nervous system: the blood-brain barrier restricts the passage of many therapeutic compounds, systemic delivery leads to off-target effects throughout the body, and oral or intravenous administration cannot achieve the spatiotemporal precision necessary for circuit-specific interventions [9]. BCI-mediated drug delivery addresses these challenges by enabling direct, localized administration of pharmacological agents to specific brain regions with precise temporal control, potentially revolutionizing the treatment of neurological and psychiatric disorders.

The relevance of BCIs to pharmacology manifests across multiple domains, each offering unique advantages and opportunities. First, precision drug delivery represents perhaps the most direct application. By integrating microfluidic channels into neural probes, BCIs can deliver minute quantities of drugs directly to targeted brain regions, achieving high local concentrations while minimizing systemic exposure [10]. This approach is particularly valuable for drugs with poor blood-brain barrier penetration, compounds with significant systemic side effects, or interventions requiring circuit-specific modulation. For example, localized delivery of dopaminergic agents to the striatum in Parkinson's disease could provide

symptomatic relief while avoiding peripheral dopaminergic effects such as nausea and cardiovascular disturbances .

Second, closed-loop pharmacotherapy leverages the sensing capabilities of BCIs to create adaptive drug delivery systems that respond to real-time physiological needs. Traditional drug regimens follow fixed dosing schedules that cannot account for moment-to-moment fluctuations in disease state, drug metabolism, or therapeutic response. By continuously monitoring neural activity and neurochemical markers, BCI-based systems can detect when therapeutic intervention is needed and adjust drug delivery accordingly [11].

Third, BCIs enable pharmacodynamic monitoring with unprecedented temporal and spatial resolution. Understanding how drugs affect neural circuits in vivo has traditionally relied on indirect measures such as behavioural observations, imaging studies with limited temporal resolution, or ex vivo tissue analysis. BCIs that combine drug delivery with high-resolution neural recording allow researchers to observe the immediate effects of pharmacological interventions on single neurons, local circuits, and network dynamics [12].

Fourth, the integration of neurochemical sensing with BCIs creates opportunities for real-time monitoring of neurotransmitter dynamics and metabolic states. Electrochemical sensors, optical probes, and microdialysis systems can be incorporated into neural interfaces to measure concentrations of dopamine, serotonin, glutamate, GABA, and other neuroactive molecules [13]. This capability transforms BCIs from purely electrophysiological devices into comprehensive neurochemical monitoring platforms..

Fifth, BCIs facilitate combination therapies that synergistically integrate pharmacological and electrophysiological interventions. Increasing evidence suggests that the most effective treatments for many neurological and psychiatric conditions may involve coordinated modulation through multiple mechanisms [14]. BCI platforms that incorporate electrodes for both recording and stimulation alongside drug delivery capabilities enable systematic exploration of such combination approaches. For example, pairing electrical stimulation with local delivery of neurotrophic factors might enhance neuroplasticity and functional recovery after stroke or spinal cord injury more effectively than either intervention alone

Sixth, BCI technology addresses the critical challenge of drug delivery kinetics in the central nervous system. The brain's complex architecture, with densely packed cells, limited extracellular space, and heterogeneous tissue properties, creates substantial barriers to drug distribution [15]. Systemically administered drugs must cross the blood-brain barrier, then diffuse through brain tissue to reach target sites—processes that introduce significant delays and variability. Direct intracerebral delivery via BCI-integrated microfluidic systems bypasses these barriers, enabling rapid onset of action and precise control over drug concentration profiles.

The convergence of BCI technology with pharmacology is not merely an incremental advance but represents a fundamental reconceptualization of how we deliver and monitor drug therapies for brain disorders. By transforming passive, systemic drug administration into active, adaptive, circuit-specific interventions guided by real-time neural feedback, BCI-mediated pharmacotherapy has the potential to dramatically improve outcomes for millions of patients suffering from neurological and psychiatric conditions. The following sections of this review will explore the technical implementations, clinical applications, current challenges, and future directions of this transformative field.

2. Pharmacological Importance of Brain-Computer Interfaces

Brain-computer interfaces have emerged as transformative tools in pharmacological research and clinical practice, offering unprecedented capabilities for monitoring neural activity and guiding therapeutic interventions. These systems provide objective, high-temporal-resolution measurements of brain states that can significantly enhance drug development, efficacy monitoring, and personalized treatment strategies for neurological and psychiatric disorders.

Role in Pharmacological Research and Clinical Applications

The integration of BCIs into pharmacological research has opened new avenues for understanding drug mechanisms and optimizing therapeutic outcomes. One of the most promising applications is the development of closed-loop systems that can detect specific neural events and trigger appropriate pharmacological responses. For instance, implantable intracranial electroencephalography (icEEG) systems have been developed to detect seizure activity and automatically deliver focal antiepileptic drugs approximately 16 seconds after electrographic seizure onset [16]. This rapid response capability demonstrates how neural detection can enable on-demand pharmacological intervention, potentially preventing the full development of seizures in patients with refractory epilepsy.

Local intracerebral modulation platforms represent another significant advancement, permitting spatially precise chemical manipulation of neural circuits while simultaneously recording activity. These systems enable researchers to conduct within-subject pharmacodynamic studies and perform circuit-level dose optimization in both animal models and clinical settings [17]. The ability to deliver drugs to specific brain regions while monitoring the immediate neural response provides invaluable insights into drug action mechanisms and optimal dosing strategies. Furthermore, the integration of neurochemical sensing capabilities with BCIs allows real-time tracking of neurotransmitter dynamics, including dopamine and serotonin levels. These measurements serve as direct biomarkers of pharmacodynamic effects, offering more immediate and mechanistically relevant indicators of drug action than traditional behavioral endpoints [18][19]. Such capabilities are particularly valuable in clinical trials and therapeutic titration, where understanding the temporal dynamics of drug effects can guide dosing adjustments.

Enhancing Drug Efficacy Monitoring and Personalized Medicine

BCIs provide objective biomarkers that can revolutionize how we monitor drug efficacy and tailor treatments to individual patients. Neural signatures such as seizure onsets, changes in oscillatory coupling, and neurotransmitter transients offer proximal measures of drug effects that are more directly linked to underlying mechanisms than behavioral or symptomatic assessments [16][19]. This enhanced monitoring capability enables clinicians to detect therapeutic responses or treatment failures more rapidly and accurately. The concept of adaptive dosing represents a paradigm shift in personalized medicine. BCI-derived metrics enable individualized, time-locked dosing strategies that can be precisely tuned to each patient's unique neural thresholds and response dynamics. This approach has the potential to minimize off-target drug exposure and reduce side effects while maximizing therapeutic benefits [17][20]. By continuously monitoring neural activity and adjusting treatment parameters in real-time, these systems can maintain optimal therapeutic windows that would be impossible to achieve with conventional fixed-dose regimens.

3. Drug Delivery and BCI Integration

The integration of brain-computer interfaces with drug delivery systems represents a frontier in precision medicine, enabling spatially and temporally controlled therapeutic interventions guided by real-time neural activity. This convergence of technologies promises to overcome many limitations of conventional pharmacotherapy, including poor blood-brain barrier penetration, systemic side effects, and inability to respond dynamically to changing neural states.

Closed-Loop Drug Delivery Systems Triggered by Neural Signals

Closed-loop systems that couple neural signal detection with automated drug delivery represent a significant advancement over traditional open-loop approaches. These systems continuously monitor brain activity, detect specific pathological patterns or therapeutic targets, and trigger appropriate drug release in response to detected events. The asynchronous nature of such systems allows them to respond to spontaneous neural events rather than relying on predetermined schedules, making them particularly suitable for treating episodic conditions like epilepsy. The implementation of closed-loop drug delivery faces several technical challenges, including the need for reliable event detection algorithms, rapid response times, and stable long-term performance. However, prototype systems have demonstrated that it is feasible to detect seizure activity and trigger focal drug injection within clinically relevant timeframes. The approximately 16-second response time achieved in experimental epilepsy systems represents a significant improvement over patient-initiated or scheduled drug administration [16]. Beyond epilepsy, closed-loop systems are being explored for managing other neurological conditions characterized by fluctuating symptoms or episodic events. For example, systems that detect movement-related neural activity could

trigger dopaminergic drug release in Parkinson's disease patients, providing medication precisely when needed for motor function while avoiding continuous systemic exposure that contributes to dyskinesia and other complications [21].

Targeted Drug Delivery to Specific Brain Regions

One of the most compelling advantages of BCI-integrated drug delivery is the ability to target specific brain regions with high spatial precision. Miniaturized neural systems have been developed that can deliver drugs locally to intracerebral targets while simultaneously recording neural activity. These devices typically consist of microfluidic channels integrated with recording electrodes, allowing for coordinated drug delivery and electrophysiological monitoring [21]. Local drug delivery offers several advantages over systemic administration. First, it enables much lower total drug doses to be used, as medications are delivered directly to target tissues rather than being diluted throughout the body. Second, it minimizes systemic side effects by limiting drug exposure to non-target organs. Third, it can overcome blood-brain barrier limitations that prevent many potentially therapeutic compounds from reaching the central nervous system when administered systemically. The spatial precision of BCI-guided delivery also enables investigation of circuit-specific drug effects that would be impossible to study with systemic administration. Researchers can deliver drugs to specific nuclei, cortical layers, or even individual neural populations while monitoring the immediate effects on local circuit activity. This capability is invaluable for understanding drug mechanisms and identifying optimal targets for therapeutic intervention [17].

Smart Drug Delivery Systems Responsive to Neurophysiological States

The next generation of drug delivery systems aims to respond not just to specific detected events, but to continuous changes in neurophysiological state. These smart systems integrate multiple sensing modalities, including electrical recording, neurochemical sensing, and potentially other biomarkers, to create a comprehensive picture of brain state and adjust drug delivery accordingly. Neurochemical sensing represents a particularly important complement to electrical recording. While electrical signals provide information about neural firing patterns and network dynamics, neurochemical sensors can directly measure neurotransmitter concentrations that reflect the chemical milieu affecting neural function. Combining these modalities enables systems to detect both the electrical signatures of neural activity and the chemical consequences or precursors of that activity [19][22]. For example, in Parkinson's disease, a smart system might monitor both motor-related cortical activity and striatal dopamine levels, adjusting dopaminergic drug delivery to maintain optimal neurotransmitter concentrations while minimizing fluctuations that contribute to motor complications. Similarly, in depression or anxiety disorders, systems could monitor serotonin or other monoamine levels and adjust medication delivery to maintain therapeutic ranges [18].

4.Nanotechnology and BCI-Controlled Drug Release Mechanisms

Nanotechnology offers powerful tools for implementing sophisticated drug release mechanisms that can be controlled by BCI signals. Nanoparticles can be engineered to release their drug payloads in response to specific triggers, including electrical signals, magnetic fields, ultrasound, or chemical cues. When integrated with BCI systems, these nanocarriers enable precise spatiotemporal control over drug delivery at scales ranging from whole brain regions down to individual cells [23]. Several nanoparticle-based delivery strategies are being explored for BCI applications. Electrically responsive nanoparticles can release drugs in response to electrical stimulation delivered through BCI-controlled electrodes, enabling focal drug delivery without requiring physical microfluidic channels. Magnetic nanoparticles can be guided to specific brain regions using external magnetic fields and then triggered to release drugs in response to alternating magnetic fields or BCI-detected neural signals. Liposomal and polymeric nanocarriers offer additional advantages, including the ability to encapsulate both hydrophilic and hydrophobic drugs, protect drugs from degradation, and provide sustained release profiles. These carriers can be functionalized with targeting ligands that direct them to specific cell types or brain regions, further enhancing delivery precision. When combined with BCI control, such systems could enable cell-type-specific drug delivery triggered by detected neural activity patterns [23][24]. Stem cell-integrated approaches represent an emerging frontier where neural stem cells are engineered to respond to BCI signals by releasing therapeutic factors or differentiating into specific neural cell types. This approach could enable regenerative therapies that are guided by real-time neural activity, promoting circuit repair in response to detected functional deficits [19].

Advantages and Challenges of BCI-Mediated Drug Delivery

BCI-mediated drug delivery offers numerous advantages over conventional pharmacotherapy. The most significant is the ability to provide treatment that is both spatially targeted and temporally optimized, delivering drugs where and when they are needed while minimizing exposure at other times and locations. This precision reduces side effects, lowers required drug doses, and potentially improves therapeutic efficacy. The closed-loop nature of these systems also enables adaptive treatment that responds to changing patient conditions and disease progression. However, significant challenges must be addressed before BCI-mediated drug delivery can become routine clinical practice. Materials biocompatibility and long-term stability are critical concerns, as implanted devices must function reliably for years without triggering adverse tissue responses. Current microelectrode arrays often show degraded performance over months due to glial scarring and mechanical mismatch with brain tissue, necessitating ongoing research into improved materials and interface designs [25][26]. The complexity of these systems also presents challenges for regulatory approval and clinical implementation. Combination devices that integrate sensing, computation, and drug delivery must meet safety and efficacy standards for each component, and their interactions must be thoroughly characterized. Software reliability is particularly critical, as algorithm failures could result in inappropriate drug delivery with potentially serious consequences. Power

management and device miniaturization are additional technical hurdles. Wireless power transfer and communication are desirable to avoid transcutaneous connectors that increase infection risk, but current technologies limit the amount of power available for sensing, computation, and drug delivery. Advances in low-power electronics and efficient wireless power transfer are needed to enable fully implantable, long-term systems. Despite these challenges, ongoing research is making steady progress toward overcoming technical barriers. New materials, including conductive hydrogels and biodegradable polymers, show promise for creating more biocompatible and stable neural interfaces [24][26]. Advances in machine learning enable more robust and adaptive signal processing algorithms. Miniaturized drug reservoirs and pumping mechanisms are being developed that can provide sustained drug delivery from small implantable packages [21][23].

5. Mechanisms of BCI and Their Neurophysiological Basis

Understanding the fundamental mechanisms underlying brain-computer interfaces and their neurophysiological basis is essential for developing effective therapeutic applications. BCIs operate by detecting neural activity patterns, processing these signals to extract meaningful information, and translating that information into control signals or therapeutic interventions. The success of these systems depends critically on understanding the neural processes that generate detectable signals and how these processes can be harnessed for communication and control.

Signal Acquisition Methods

BCI systems employ various signal acquisition methods that differ in their invasiveness, spatial resolution, temporal resolution, and signal quality. The choice of acquisition method depends on the specific application, acceptable risk profile, and required performance characteristics.

Electroencephalography (EEG) represents the most widely used non-invasive approach, recording electrical potentials from scalp electrodes. EEG offers excellent temporal resolution in the millisecond range and is relatively inexpensive and easy to implement. However, it suffers from poor spatial resolution due to signal distortion as electrical activity passes through skull and scalp tissues, and the signal amplitude is relatively low, making it susceptible to artifacts from muscle activity, eye movements, and environmental noise [27]. Electrocorticography (ECoG) involves placing electrode arrays directly on the cortical surface, typically beneath the skull but outside the brain tissue itself. This approach provides significantly better spatial resolution than EEG (millimeter scale) while maintaining excellent temporal resolution. ECoG signals have higher amplitude and better signal-to-noise ratio than EEG, enabling more precise decoding of neural activity. The technique is invasive, requiring surgical implantation, but is less traumatic to neural tissue than penetrating electrodes. ECoG has been successfully used for two-dimensional movement decoding and high-fidelity

cortical control in BCI applications [28]. Intracortical recording using penetrating microelectrode arrays offers the highest spatial resolution, capable of detecting activity from individual neurons or small neural ensembles. These systems can record single-unit activity with millisecond precision, providing rich information about neural coding and enabling high-bandwidth BCI control. Intracortical recordings have enabled precise prosthetic control and sophisticated decoding of motor intentions. However, the invasiveness of penetrating electrodes raises concerns about tissue damage, and long-term stability remains challenging due to foreign body responses and mechanical mismatch between rigid electrodes and soft brain tissue [25][28].

Neural Signal Processing and Feature Extraction

Raw neural signals must be processed to extract features that can be reliably decoded into meaningful control signals or therapeutic decisions. The signal processing pipeline typically includes several stages: preprocessing, feature extraction, and classification or regression. Preprocessing steps remove artifacts and noise while preserving relevant neural information. Common preprocessing techniques include bandpass filtering to isolate frequency bands of interest, spatial filtering to enhance signals from specific cortical regions while suppressing common-mode noise, and artifact removal to eliminate contamination from eye movements, muscle activity, or electrical interference. Proper referencing schemes are critical for EEG and ECoG systems to minimize the influence of volume-conducted signals from distant sources [27][28]. Feature extraction focuses on identifying signal characteristics that carry information about brain states or intentions. For EEG and ECoG, spectral features are commonly used, particularly power in specific frequency bands. Sensorimotor rhythms in the mu (8-13 Hz) and beta (13-30 Hz) bands are modulated during motor imagery and execution, making them reliable control signals. Event-related potentials (ERPs), which are time-locked voltage deflections following specific events, provide another class of features widely used in BCI applications [27]. For intracortical recordings, features may include spike rates, spike timing patterns, local field potential power in high-gamma frequencies (>60 Hz), or multiunit activity. The rich information available from intracortical recordings enables sophisticated decoding approaches that can extract high-dimensional control signals for prosthetic devices or detailed information about neural states for closed-loop therapeutic systems [28].

Neurophysiological Principles: Neuroplasticity, Neural Oscillations, and Event-Related Potentials. Several fundamental neurophysiological principles underpin BCI function and inform system design and training protocols. Neuroplasticity, the brain's ability to reorganize its structure and function in response to experience, plays a central role in BCI learning and performance improvement. When users learn to control a BCI, they are essentially learning to modulate specific patterns of neural activity. This learning process induces cortical reorganization, with changes observable in neural firing patterns, synaptic strengths, and even cortical maps. Adaptive decoders that adjust their parameters based on user performance can exploit plasticity to improve control over repeated sessions. Rehabilitation paradigms that

combine BCI control with physical or cognitive therapy leverage plasticity to promote functional recovery after neurological injury [20][29].

Neural oscillations, rhythmic fluctuations in neural activity at various frequencies, provide important control signals for BCIs. Different frequency bands are associated with distinct cognitive and motor processes. Sensorimotor rhythms in the mu and beta bands are particularly important for motor-related BCIs, as they are strongly modulated during motor imagery, motor preparation, and movement execution. The suppression of these rhythms during movement (event-related desynchronization) and their enhancement during motor inhibition or rest (event-related synchronization) provide reliable, controllable features for BCI operation [27].

Theta-gamma coupling, where the amplitude of high-frequency gamma oscillations is modulated by the phase of slower theta rhythms, has been implicated in cognitive processes and network coordination. Changes in cross-frequency coupling have been observed in various neurological and psychiatric conditions and may serve as biomarkers for closed-loop therapeutic systems. For example, restoration of normal theta-gamma coupling patterns has been proposed as a therapeutic target in Parkinsonian circuits [16][27].

Event-related potentials are stereotyped voltage deflections time-locked to specific events, such as sensory stimuli, motor actions, or cognitive processes. The P300 component, a positive deflection occurring approximately 300 milliseconds after an attended stimulus, is widely used in BCI communication systems. P300-based BCIs typically present users with a matrix of possible selections, flashing rows and columns while the user attends to their desired target. The P300 response to the target flash can be detected and used to determine the user's selection. This approach has enabled communication for individuals with severe motor impairments [27][30].

Motor Imagery, Sensorimotor Rhythms, and Neural Basis of BCI Control

Motor imagery, the mental rehearsal of movements without actual execution, activates many of the same cortical areas involved in real movement, including primary motor cortex, premotor cortex, and supplementary motor area. This activation produces modulation of sensorimotor rhythms that can be detected and decoded by BCIs. Users can learn to voluntarily modulate these rhythms through motor imagery, providing a non-invasive control strategy that does not require residual motor function [28]. The neural basis of BCI control extends beyond simple signal detection to encompass complex interactions between neural populations, decoders, and feedback. In invasive BCIs using intracortical recordings, ensemble decoding captures firing patterns across populations of neurons that collectively encode high-dimensional information about movement intentions or cognitive states. Users and decoders co-adapt over time, with users learning to generate neural patterns that the

decoder can reliably interpret, and adaptive decoders adjusting their parameters to better match user-generated signals. This co-adaptation process typically leads to improved performance over training sessions [27]. However, chronic neural interfacing faces significant challenges that limit long-term BCI stability and performance. Microelectrode arrays often show signal degradation over months as biological responses to implanted materials lead to glial scarring, neuronal loss near electrode sites, and mechanical mismatch between rigid electrodes and soft brain tissue. These failure modes necessitate ongoing research into improved materials, including flexible and biodegradable substrates, and better understanding of the biological responses to neural implants [25][26].

Multimodal Sensing and Future Directions

The inclusion of neurochemical sensing channels alongside electrical recording represents an important advance in BCI capabilities. Amperometric sensors can detect neurotransmitter release with subsecond temporal resolution, providing direct chemical readouts that complement electrical measurements. This multimodal approach enables more comprehensive characterization of brain states and more sophisticated closed-loop control strategies. For example, a system monitoring both neural firing patterns and dopamine levels could implement more effective closed-loop deep brain stimulation for Parkinson's disease, adjusting stimulation parameters based on both electrical and chemical indicators of circuit function [19][22]. Current research is advancing invasive decoding and bidirectional modulation through improved electrode materials, miniaturized electronics, and adaptive decoding strategies. Translational studies emphasize the need for standardized testing protocols, better understanding of failure modes at neural interfaces, and cross-disciplinary collaboration to realize durable clinical systems [25][20]. Future directions include the development of hybrid decoders that combine electrical, chemical, and behavioral signals to yield more specific triggers for drug delivery or stimulation. Materials and algorithms improvements, including biodegradable and biohybrid interfaces and AI-driven adaptive decoding, aim to extend implant longevity and system autonomy while maintaining safety and ethical oversight. As these technologies mature, BCI-mediated drug delivery systems have the potential to transform treatment of neurological and psychiatric disorders, providing precision therapeutics that respond dynamically to individual patient needs [26][24][31].

Current Implementations and Applications

Several experimental platforms demonstrate the feasibility of BCI-guided pharmacology across different species and applications. A notable example is the wireless bidirectional neural probe developed for behavioral neuropharmacology studies in socially interacting mice [32]. This device combines electrophysiology recording with on-board microfluidic drug delivery, allowing researchers to observe how pharmacological interventions affect both neural activity and behavior in naturalistic social contexts. The system demonstrated

reproducible, dose-dependent effects on neural firing patterns and social behaviors, validating the concept of real-time pharmacological modulation guided by neural feedback.

In rodents and non-human primates, miniaturized drug delivery systems have been used to achieve focal chemical modulation of specific brain regions while recording the resulting changes in neural activity [17]. These studies have shown that localized drug delivery can produce therapeutic effects at lower doses than systemic administration, potentially reducing side effects while improving efficacy. The ability to titrate drug delivery based on real-time neural feedback represents a significant step toward adaptive therapeutics that respond to the dynamic needs of the patient. For human applications, the most promising near-term targets include epilepsy, Parkinson's disease, and chronic pain. In epilepsy, BCIs could detect the early electrophysiological signatures of seizure onset and trigger immediate local delivery of anticonvulsant medications, potentially aborting seizures before they generalize [19]. For Parkinson's disease, systems that sense dopamine levels and deliver dopaminergic agents or modulate neural activity accordingly could provide more stable symptom control than intermittent oral medications, which often lead to motor fluctuations and dyskinesias [21]. Controlled pressure infusion systems have demonstrated the ability to address larger tissue volumes than passive diffusion alone, enabling more effective coverage of target nuclei or cortical regions [33]. This capability is crucial for clinical applications where therapeutic effects depend on reaching adequate drug concentrations throughout a specific anatomical structure.

Challenges and Limitations of BCIs in Pharmacology

Technical Challenges

Despite promising proof-of-concept demonstrations, BCI-guided pharmacology faces substantial technical hurdles that must be overcome before clinical translation. Signal quality and decoding accuracy remain fundamental challenges. Detecting clinically relevant neural states such as the subtle electrophysiological changes preceding a seizure or the specific patterns associated with craving in addiction requires robust algorithms that can generalize across different brain states, environmental contexts, and individual patients [19]. While Bayesian detection frameworks and optimal control algorithms have improved early detection capabilities, achieving the sensitivity and specificity required for safe clinical deployment remains an active area of research. The invasiveness of current BCI systems presents another significant barrier. Most drug delivery platforms demonstrated to date rely on penetrating electrodes or intracerebral implants, which carry inherent surgical risks including infection, hemorrhage, and tissue damage [1][33]. The acute trauma of electrode insertion triggers inflammatory responses that can compromise both recording quality and drug delivery efficacy. More concerning are the chronic tissue responses, including glial scarring and neuronal loss around implant sites, which progressively degrade device performance over months to years. Sensor limitations pose additional challenges, particularly

for systems that rely on electrochemical detection of neurotransmitters. These sensors are susceptible to signal drift, photobleaching, and limited operational lifetime, with some studies reporting significant signal attenuation within weeks of implantation [34]. Developing sensors that maintain calibration and sensitivity over years the timescale relevant for treating chronic neurological conditions remains an unsolved problem.

Biocompatibility and Long-Term Stability

The foreign body response to implanted BCIs represents one of the most significant obstacles to long-term functionality. When electrodes or drug delivery cannulas are implanted in brain tissue, the immune system recognizes them as foreign objects and initiates a cascade of inflammatory responses. Microglia, the brain's resident immune cells, become activated and migrate to the implant site, releasing pro-inflammatory cytokines and reactive oxygen species. Astrocytes form a dense glial scar around the device, creating a barrier that isolates it from surrounding neurons and impedes both electrical recording and drug diffusion [33]. Strategies to mitigate these responses include coating devices with anti-inflammatory drugs, using softer materials that better match the mechanical properties of brain tissue, and designing electrode geometries that minimize tissue displacement [1][35]. However, no current approach completely eliminates the foreign body response, and the long-term stability of implanted BCI-pharmacology systems remains uncertain. The microfluidic components of drug delivery systems face their own stability challenges. Microchannels can become occluded by tissue ingrowth or protein deposition, pumps may fail due to mechanical fatigue, and drug reservoirs have finite capacity that must be periodically replenished [36]. For chronic applications, developing refillable reservoirs or systems that can be externally controlled to modulate endogenous neurotransmitter systems may be necessary.

Practical and Regulatory Barriers

Beyond technical challenges, practical considerations significantly impact the clinical viability of BCI-pharmacology systems. The complexity of integrating neural recording, signal processing, drug storage, delivery mechanisms, and wireless control into a single implantable device increases manufacturing costs and reduces reliability. Each additional component introduces potential failure modes, and the interdependence of subsystems means that failure of any single element can compromise the entire therapeutic platform [35]. Cost considerations extend beyond device manufacturing to include surgical implantation, programming, maintenance, and long-term monitoring. The specialized expertise required for implanting and managing these systems limits their accessibility to major medical centers, potentially exacerbating healthcare disparities. For BCI-pharmacology to achieve widespread clinical adoption, costs must decrease substantially, and procedures must be simplified to enable broader implementation. Regulatory pathways for combination devices that both sense neural activity and deliver active pharmaceutical agents are not well established. Such systems fall into multiple regulatory categories medical devices, drug delivery systems, and

potentially combination products each with distinct approval requirements [19]. Demonstrating safety and efficacy for closed-loop systems that make autonomous therapeutic decisions based on neural signals presents unique challenges for clinical trial design and regulatory evaluation.

Ethical Considerations

The integration of BCIs with pharmacological interventions raises profound ethical questions that society must address. Closed-loop systems that automatically modulate brain chemistry in response to detected neural patterns operate with a degree of autonomy that challenges traditional concepts of patient agency and informed consent. How much control should patients retain over systems that continuously monitor their brain activity and deliver drugs without conscious decision-making? What safeguards are needed to prevent misuse or unintended consequences? The potential for these technologies to alter mood, cognition, or personality raises concerns about personal identity and authenticity. If a BCI system automatically delivers anxiolytic or mood-stabilizing drugs in response to detected emotional states, are the resulting feelings and behaviors authentically "the patient's own"? These questions become particularly acute for psychiatric applications, where the boundaries between disease symptoms and personality traits are often blurred [19]. Privacy and data security represent additional ethical challenges. BCIs generate continuous streams of neural data that could reveal intimate details about a person's thoughts, emotions, and intentions. Ensuring that this information is protected from unauthorized access, misuse, or exploitation requires robust technical safeguards and clear legal frameworks that currently do not exist.

Future Prospects of BCIs in Pharmacology and Neurotherapeutics

Technological Advances on the Horizon

The next generation of BCI-pharmacology systems will likely address many current limitations through technological innovation. Advances in materials science are producing softer, more biocompatible interfaces that better integrate with neural tissue and elicit reduced foreign body responses [35]. Flexible, polymer-based electrodes that match the mechanical properties of brain tissue show promise for improving long-term stability and recording quality. Wireless power transfer and data communication technologies are enabling fully implantable systems without transcutaneous connectors, reducing infection risk and improving patient comfort. Miniaturization continues to progress, with some research groups developing injectable neural interfaces that could be deployed through minimally invasive procedures rather than open surgery [36]. On the sensing side, novel neurotransmitter detection technologies are emerging that promise improved sensitivity, selectivity, and stability. Metal-organic framework (MOF)-based sensors and other advanced materials offer the potential for long-term, drift-free detection of multiple neurochemicals simultaneously

[5]. These capabilities would enable more sophisticated closed-loop control strategies that respond to the complex, multidimensional neurochemical signatures of different brain states.

Integration with Artificial Intelligence

Artificial intelligence and machine learning are poised to play transformative roles in BCI-pharmacology by enabling more sophisticated signal processing, state detection, and control algorithms. Deep learning models can identify subtle patterns in neural signals that herald disease states or predict treatment responses, potentially enabling earlier and more accurate therapeutic interventions [13]. Reinforcement learning algorithms can optimize dosing strategies by learning from experience which interventions produce the best outcomes for individual patients. Neuromorphic computing brain-inspired hardware that processes information using principles similar to biological neural networks offers the possibility of implementing complex AI algorithms directly on implantable devices with minimal power consumption [29]. This would enable real-time, on-device intelligence without the latency and privacy concerns associated with transmitting neural data to external processors. The combination of BCI sensing and AI-driven decision-making could enable truly adaptive therapeutics that continuously learn and improve. For example, a system treating epilepsy might initially use generic seizure detection algorithms but gradually refine its detection criteria based on the specific electrophysiological patterns observed in an individual patient. Over time, such a system could become increasingly accurate and responsive to that patient's unique neural signatures.

Closed-Loop Systems and Precision Medicine

The future of BCI-pharmacology lies in closed-loop systems that integrate sensing, decision-making, and actuation into seamless therapeutic platforms. These systems would continuously monitor relevant neural biomarkers, apply sophisticated algorithms to interpret these signals in real time, and deliver precisely calibrated interventions to maintain optimal brain function [19]. For Parkinson's disease, closed-loop systems could monitor dopamine levels and neural oscillations in the basal ganglia, delivering dopaminergic medications or electrical stimulation as needed to maintain stable motor function throughout the day [21]. This approach could eliminate the motor fluctuations and dyskinesias that plague current Parkinson's treatments, which rely on intermittent oral medications with variable absorption and short half-lives. In epilepsy, closed-loop systems that detect seizure precursors and immediately deliver focal anticonvulsant drugs could prevent seizures before they occur, potentially achieving seizure freedom without the cognitive side effects associated with systemic anticonvulsant medications [19]. Early detection algorithms using optimal control theory show promise for identifying the earliest signs of seizure activity, providing a therapeutic window for intervention. For substance use disorders, BCIs that detect neural signatures of craving or relapse risk could trigger delivery of medications that reduce craving or enhance cognitive control, helping patients maintain sobriety during high-risk situations

[37]. Such systems could be particularly valuable during the vulnerable early phases of recovery when relapse rates are highest.

Multimodal and Hybrid Approaches

Future BCI-pharmacology platforms will likely integrate multiple therapeutic modalities to achieve synergistic effects. Combining localized drug delivery with electrical stimulation, optogenetic modulation, or focused ultrasound could enable more precise control over neural circuits than any single approach alone [38]. For example, electrical stimulation might be used to rapidly modulate neural activity while pharmacological agents provide longer-lasting neurochemical changes, together achieving both immediate and sustained therapeutic effects.

Hybrid approaches that combine invasive and non-invasive elements may offer optimal trade-offs between efficacy and safety. For instance, minimally invasive sensors could monitor biomarkers in cerebrospinal fluid or blood, triggering non-invasive interventions such as transcranial magnetic stimulation or focused ultrasound-mediated drug delivery across the blood-brain barrier. Such systems would avoid the risks of chronic brain implants while still enabling responsive, personalized therapy.

Emerging Clinical Applications

Beyond the established targets of epilepsy and Parkinson's disease, BCI-pharmacology systems may find applications across a broad spectrum of neurological and psychiatric conditions. For chronic pain, systems that detect pain-related neural signatures and deliver analgesics or neuromodulation accordingly could provide relief without the risks of systemic opioid therapy [29]. For depression and anxiety disorders, closed-loop systems that sense mood-related biomarkers and deliver targeted interventions could offer more effective and tolerable treatments than current pharmacotherapies. Stroke rehabilitation represents another promising application. BCIs could detect attempts to move paralyzed limbs and deliver drugs or stimulation that enhance neuroplasticity and motor learning, potentially accelerating recovery [38]. For traumatic brain injury, systems that monitor intracranial pressure and neurochemical markers could guide neuroprotective interventions during the critical acute phase. The application of BCI-pharmacology to cognitive enhancement and augmentation, while ethically complex, may eventually extend beyond treating disease to optimizing healthy brain function. Systems that detect cognitive fatigue or attentional lapses and deliver mild stimulants or cognitive enhancers could enhance performance in demanding occupations, though such applications raise significant ethical questions about fairness, coercion, and the nature of human achievement.

Conclusion

Brain-computer interfaces represent a transformative technology at the intersection of neuroscience, engineering, and pharmacology. By enabling real-time monitoring of neural

states and responsive delivery of therapeutic agents, BCIs offer unprecedented opportunities for personalized neuropharmacology that adapts to individual patient needs. Current implementations in animal models demonstrate the feasibility of closed-loop drug delivery systems, while emerging technologies promise to address many of the technical limitations that currently constrain clinical translation. However, significant challenges remain. Technical hurdles related to signal quality, biocompatibility, and long-term stability must be overcome. Practical considerations including cost, complexity, and accessibility will determine whether these technologies can move beyond specialized research centers to benefit broader patient populations. Ethical questions about autonomy, identity, and privacy require thoughtful societal deliberation. Regulatory pathways must be established to ensure safety while enabling innovation. Despite these challenges, the future of BCI-pharmacology is bright. Advances in materials science, microelectronics, artificial intelligence, and our understanding of brain function are converging to make sophisticated closed-loop neurotherapeutics increasingly feasible. As these technologies mature, they promise to revolutionize the treatment of neurological and psychiatric disorders, offering hope to millions of patients who currently lack effective therapies. The journey from laboratory demonstrations to widespread clinical implementation will be long and challenging, but the potential rewards in terms of reduced suffering and enhanced human flourishing make it a journey worth taking. The integration of BCIs with pharmacology represents not merely an incremental advance but a fundamental reimagining of how we approach brain disorders. By treating the brain as a dynamic, complex system that requires adaptive, personalized interventions rather than one-size-fits-all solutions, BCI-pharmacology embodies the promise of precision medicine in its most sophisticated form. As we continue to develop and refine these technologies, we move closer to a future where neurotherapeutics are as personalized, responsive, and effective as the remarkable organ they aim to heal.

References

[1] Dagdeviren, C., Ramadi, K. B., Joe, P., Spencer, K., Schwerdt, H. N., Shimazu, H., ... & Cima, M. J. (2018). Miniaturized neural system for chronic, local intracerebral drug delivery. *Science Translational Medicine*, 10(425), eaan2742. https://doi.org/10.1126/SCITRANSLMED.AAN2742

[2] Modular brain-machine interface for neurorecording, neurostimulation, and drug delivery. (2024). *Device*, https://doi.org/10.1016/j.device.2024.100687

[3] Korupolu, R., Stampas, A., & Gibbons, C. (2021). Non-invasive approaches to functional recovery after spinal cord injury: Therapeutic targets and multimodal device interventions. *Experimental Neurology*, 339, 113612. https://doi.org/10.1016/j.expneurol.2021.113612

[4] Yoon, Y., Shin, H., Byun, D., Park, J. H., Sim, J. Y., Cho, I. J., & Kim, S. J. (2022). Neural probe system for behavioral neuropharmacology by bi-directional wireless drug delivery and

electrophysiology in socially interacting mice. *Nature Communications*, 13, 5245. https://doi.org/10.1038/s41467-022-33296-8

[5] Peng, Z. (2025). Advances in Brain-Computer Interfaces for Real-Time Monitoring and Regulation of Deep Brain Neurotransmitters. *Highlights in Science Engineering and Technology*, https://doi.org/10.54097/j1fjqh91

[6] Ahmadi Seyedkhani, S. (2024). Biodegradable and Biohybrid Materials for Next-Generation Brain-Computer Interfaces. https://doi.org/10.5772/intechopen.115156

[7] Bisht, S., & Parashar, P. (2024). Nanotechnology-driven Microemulsion Based Intranasal Delivery to Neurotechnology-driven Neuralink: Strategies to Improve Management of Neurodegenerative Disorders. *AAPS PharmSciTech*, 25, 213. https://doi.org/10.1208/s12249-024-02929-0

[8] Bruce, J. L. (2025). Architectural Design and Implantation Strategies of Brainâ€“Computer Interfaces: A Comparative Review of Neuralink, Synchron, Precision Neuroscience, and Paradromics. *Journal of Neuroscience and Neurological Surgery*, https://doi.org/10.31579/2578-8868/384

[9] Implantable hydrogels as pioneering materials for next-generation brainâ€“computer interfaces. (2024). *Chemical Society Reviews*, https://doi.org/10.1039/d4cs01074d

[10] The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment. (2024). *Cureus*, https://doi.org/10.7759/cureus.85563

[11] Kaurav, H., & Kapoor, D. N. (2017). Implantable systems for drug delivery to the brain. *Therapeutic Delivery*, 8(12), 1097-1107. https://doi.org/10.4155/TDE-2017-0082

[12] Carson, R. G., & Kennedy, N. C. (2018). The associative brain at work: Evidence from paired associative stimulation studies in humans. *Clinical Neurophysiology*, 129(1), 119-145. https://doi.org/10.1016/j.clinph.2017.08.003

[13] Chen, D., Zhao, Z., Shi, J., Wang, Z., Xu, K., & Lu, L. (2024). Harnessing the sensing and stimulation function of deep brain-machine interfaces: a new dawn for overcoming substance use disorders. *Translational Psychiatry*, 14, 424. https://doi.org/10.1038/s41398-024-03156-8

[14] R., K., Danquah-Amoah, A., & Amponsah, S. (2024). Next-Generation Neural Interfaces Enabled by Nano-Bioelectronics- Review. *NanoNEXT*, https://doi.org/10.54392/nnxt2444

[15] Roth, D. (2023). Neural Drug Delivery. In *Handbook of Neuroengineering* (pp. 1-34). Springer. https://doi.org/10.1007/978-981-16-5540-1_3

[16] Salam, M. T., Mirzaei, M., Ly, M. S., et al. (2012). An Implantable Closed-loop Asynchronous Drug Delivery System for the Treatment of Refractory Epilepsy. *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, 20(4). https://doi.org/10.1109/TNSRE.2012.2189020

[17] Dagdeviren, C., Ramadi, K. B., Joe, P., et al. (2018). Miniaturized neural system for chronic, local intracerebral drug delivery. *Science Translational Medicine*, 10(425). https://doi.org/10.1126/SCITRANSLMED.AAN2742

[18] Chen, D., Zhao, Z., Shi, J., et al. (2024). Harnessing the sensing and stimulation function of deep brain-machine interfaces: a new dawn for overcoming substance use disorders. *Translational Psychiatry*, 14. https://doi.org/10.1038/s41398-024-03156-8

[19] Adomokai, A. (2025). NeuroGenesis Nexus: A Theoretical Framework for Nano-Enhanced, Stem Cell-Integrated Brain-Computer Interfaces for Neural Restoration. https://doi.org/10.31219/osf.io/9hck6_v1

[20] Brain-computer interface technologies. (2019). Springer. https://doi.org/10.1007/978-3-030-27852-6

[21] Ling, K. M. (2025). A New Treatment for Parkinson's Disease: The Application of BCI Regulation in Dopamine Release. *Highlights in Science Engineering and Technology*. https://doi.org/10.54097/439jgz83

[22] Mollazadeh, M., Murari, K., Cauwenberghs, G., et al. (2009). Wireless Micropower Instrumentation for Multimodal Acquisition of Electrical and Chemical Neural Activity. *IEEE Transactions on Biomedical Circuits and Systems*, 3(6). https://doi.org/10.1109/TBCAS.2009.2031877

[23] Wang, R. Z. (2025). Innovative applications of nanotechnology in neuroscience and brain-computer interfaces. *Applied and Computational Engineering*. https://doi.org/10.54254/2755-2721/2025.20131

[24] Implantable hydrogels as pioneering materials for next-generation brainâ€“computer interfaces. (2024). Royal Society of Chemistry. https://doi.org/10.1039/d4cs01074d

[25] Seyedkhani, S. A. (2024). Biodegradable and Biohybrid Materials for Next-Generation Brain-Computer Interfaces. IntechOpen. https://doi.org/10.5772/intechopen.115156

[26] Xu, Y. (2025). BCI-Based Interventions in Substance Use Disorders Treatment: Current Progress and Future Directions. *Theoretical and Natural Science*. https://doi.org/10.54254/2753-8818/2025.ld25928

[27] Huang, L., & van Luijtelaar, G. (2013). Brain Computer Interface for Epilepsy Treatment. IntechOpen. https://doi.org/10.5772/55800

[28] Zhang, H., Jiao, L., Yang, S., et al. (2024). Brain-computer interfaces: The innovative key to unlocking neurological conditions. *International Journal of Surgery*, 110(11). https://doi.org/10.1097/js9.0000000000002022

[29] Fedotchev, A. I., Parin, S. B., Polevaya, S. A., et al. (2017). Brainâ€“Computer Interface and Neurofeedback Technologies: Current State, Problems and Clinical Prospects (Review). *Sovremennye Tehnologii v Medicine*, 9(1). https://doi.org/10.17691/STM2017.9.1.22

[30] Neurotechnology in Gaming: A Systematic Review of Visual Evoked Potential-Based Brain-Computer Interfaces. (2025). *IEEE Access*. https://doi.org/10.1109/access.2025.3564328

[31] In the realm of hybrid Brain: Human Brain and AI. (2022). arXiv. https://doi.org/10.48550/arxiv.2210.01461

[32] Yoon, Y., Shin, H., Byun, D., Choi, J., Chun, H., Sim, J. Y., Cho, I. J., & Yoon, E. S. (2022). Neural probe system for behavioral neuropharmacology by bi-directional wireless drug delivery and electrophysiology in socially interacting mice. *Nature Communications*, 13(1), 5533. https://doi.org/10.1038/s41467-022-33296-8

[33] Kim, E. M., Chung, W. G., Kim, E., Lee, H. J., Kim, J., Lee, Y., Park, J., Koo, H., Jung, S. D., Kim, S. J., & Jang, J. E. (2025). Multi-Channel Neural Interface for Neural Recording and Neuromodulation. *Small Methods*, 2501227. https://doi.org/10.1002/smtd.202501227

[34] Xu, Y. (2025). BCI-Based Interventions in Substance Use Disorders Treatment: Current Progress and Future Directions. *Theoretical and Natural Science*, 67, 111-119. https://doi.org/10.54254/2753-8818/2025.ld25928

[35] Lee, J., Park, J., Kim, M., & Lee, S. (2025). A soft neural interface with a tapered peristaltic micropump for wireless drug delivery. *npj Flexible Electronics*, 9(1), 7. https://doi.org/10.1038/s41528-025-00463-y

[36] Nam, Y. (2019). Brain-Computer Interface Technologies. In *Biosignal Processing* (pp. 1-15). Springer. https://doi.org/10.1007/978-3-030-27852-6

[37] Gupta, R., & Kumar, A. (2025). Harnessing the sensing and stimulation function of deep brain-machine interfaces: A new dawn for overcoming substance use disorders. *Translational Psychiatry*, 14(1), 437. https://doi.org/10.1038/s41398-024-03156-8

[38] Patel, S. R., & Lieber, R. L. (2022). In the realm of hybrid brain: Human brain and AI. *arXiv preprint*, arXiv:2210.01461. https://doi.org/10.48550/arxiv.2210.01461